CME Reports Today as Stock Breaks Above Mean Target

CME Group crossed a notable threshold this week: the stock at $295.31 has finally broken above the mean analyst price target of $293.56, arriving at its Q3 earnings release on the front foot after a 6.2% weekly gain.

The move changes the geometry of the analyst debate. A week ago the previous note here flagged roughly 5% upside to the then-mean target of $292.88. That gap has now closed, and the stock sits fractionally above the consensus. The directional split on the Street remains the same. Morgan Stanley holds Overweight at $337 and Wells Fargo at $315, both raised within the past two weeks. Barclays sits at Equal-Weight with a $281 target, below the current price, and JP Morgan maintains Underweight at $250. With the stock now trading through the mean, the bears at the lower end of the range carry more weight than they did when the stock was at $278. Factor scores lean positive: the analyst recommendation differential ranks in the 97th percentile of the universe, EPS surprise comes in at the 62nd percentile, and the dividend score ranks 75th. Value remains the weak point, with EV/EBITDA at 20.2x and the PE multiple around 22.9x, both drifting higher over the past month.

The bull case centres on Market Data revenue growing 14.5% in the most recent quarter and a free cash flow record that has funded more than 14 consecutive years of dividend growth. Bears focus on a rate-cutting cycle that compresses interest rate futures volumes, with one set of estimates pointing to revenue growth of roughly 5.4% for the full year, short of the consensus expectation near 6%. Competitive pressure from FMX is a secondary drag, cited as a source of pricing friction that limits near-term margin expansion. Today's Q3 print will be the first hard data point to adjudicate between those two positions.

Short positioning offers little drama on its own, and nothing there contradicts the constructive price action. Short interest in CME runs at 1.55% of the free float, up about 2.9% on the week but down roughly 2% over the past month. The borrow market is extremely loose: availability is essentially uncapped relative to shares on loan, and the cost to borrow has eased sharply over the past week to around 0.35%. The ORTEX short score of 31.2 places CME well into undemanding territory. Options positioning has softened slightly from recent defensive readings. The put/call ratio at 1.10 is a touch below its 20-day average of 1.13, a half-standard-deviation move toward calls, suggesting the options market has reduced its hedging bias modestly into the print rather than adding to it.

Among peers, CBOE gained 7.8% on the week and TW added 8.5%, both ahead of CME's 6.2%. MIAX led the group with nearly 9.7%. CME has outperformed ICE, up 1.4% on the week, and NDAQ, also up about 1.4%, though it trails the higher-beta names in the exchange complex. The pattern suggests the sector broadly has caught a bid, with CME capturing a meaningful share of it without leading.

Retail attention is an outlier worth noting. The Wikipedia views signal for CME shows a z-score of 1.84 against the company's own 90-day history, the highest attention reading in that window. That reflects earnings-driven interest rather than any operational shift, but it does confirm the print today is drawing unusual traffic to the name.

The number to watch this morning is average daily volume in interest rate futures, where the tension between a still-elevated rate environment and the trajectory of Fed cuts will determine whether the bull or bear frame on 2027 earnings holds.